Insuman Comb 30 Solostar

Insulin human, the active ingredient in Insuman Comb 30 Solostar, is a human insulin presented as a solution for injection for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients, helping to regulate blood glucose levels.

GNH USA supplies Insuman Comb 30 Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Comb 30 Solostar is a human insulin used in the management of diabetes mellitus and related metabolic disorders.

- Type 1 diabetes mellitus: provides basal and prandial insulin to achieve glycemic control. - Type 2 diabetes mellitus: supplements endogenous insulin to lower elevated blood glucose. - Diabetic ketoacidosis (adjunct therapy): contributes to rapid reduction of hyperglycaemia when combined with other insulin regimens.

Insuman Comb 30 Solostar may be associated with a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: symptoms of low blood sugar such as shakiness, sweating, and confusion. - Injection‑site reactions: redness, swelling, or pain at the injection site. - Lipodystrophy: localized thickening or loss of subcutaneous fat. - Weight gain: modest increase in body weight due to improved glucose utilization. - Mild allergic reactions: itching or rash at the site of administration.

Serious or Rare Side Effects: - Severe hypoglycaemia: loss of consciousness or seizures requiring immediate assistance. - Anaphylactic reaction: rapid onset of breathing difficulty, swelling, and hypotension. - Hypokalemia: low serum potassium levels, potentially causing cardiac arrhythmias. - Insulin‑induced oedema: peripheral swelling, especially in the lower extremities. - Serum insulin antibodies: rare immune response that may alter insulin effectiveness. - Necrotising fasciitis: extremely rare but serious infection at injection sites.

When using Insuman Comb 30 Solostar, several safety considerations are recommended.

- Blood‑glucose monitoring: check levels frequently to avoid hypoglycaemia. - Dose adjustment during illness: reduce or increase insulin based on carbohydrate intake and stress response. - Renal impairment: use caution and consider lower doses as insulin clearance may be reduced. - Concomitant hypoglycaemic agents: monitor for additive glucose‑lowering effects. - Pregnancy and lactation: discuss risks and benefits with a healthcare professional. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insuman Comb 30 Solostar can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of hypoglycaemia, complicating detection. - MAO‑inhibitors: can potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk. - Sulfonylureas: additive hypoglycaemic effect may require dose reduction.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose, necessitating insulin dose adjustment. - ACE inhibitors and ARBs: can enhance insulin sensitivity, modestly lowering glucose. - Oral contraceptives: may affect insulin requirements during hormonal changes. - Corticosteroids: increase insulin resistance, potentially requiring higher insulin doses.